WeVote
Log In

Bill

WeVote Research Nonpartisan
Bill Summary · HB 1055

Summary of House Bill 1055 (HB 1055)

Purpose of the Bill

House Bill 1055 aims to establish coverage for the diagnosis and treatment of Alzheimer’s disease and other dementia-related diseases under the State and Public School Life and Health Insurance Program. The bill seeks to enhance access to effective treatments and diagnostic services, thereby potentially improving health outcomes for affected individuals.

Key Provisions

  • Coverage Mandate: The bill mandates that all state and public school employee health benefit plans must cover:

    • Diagnosis and treatment of Alzheimer’s disease and other dementia-related diseases.
    • Treatments or medications approved by the U.S. Food and Drug Administration (FDA) that are intended to slow the progression of these diseases.
    • Necessary diagnostic testing to determine the appropriate use of these treatments.

  • Implementation Timeline: The coverage requirements will apply to plans offered, issued, or renewed on or after January 1, 2026.

  • Exemption from Step Therapy: Treatments covered under this bill will not be subject to step therapy protocols, which often require patients to try less expensive treatments before moving on to more costly options.

Fiscal Impact

  • Projected Costs: The estimated cost of implementing this coverage is projected to be between $2 million and $4 million annually, which represents approximately 0.4% to 0.7% of medical claims for the Employee Benefits Division (EBD) plan.
  • New Treatments: The bill includes coverage for newly FDA-approved treatments such as Legembi and Kisunla, which target amyloid-beta proteins and have shown efficacy in slowing cognitive decline in early Alzheimer's disease.

Affected Parties

  • State Employees and Public School Employees: The primary beneficiaries of this bill will be state and public school employees who are diagnosed with Alzheimer’s disease or other dementia-related conditions.
  • Healthcare Providers: Physicians will have the authority to prescribe treatments based on evidence-based guidelines, enhancing their ability to manage patient care effectively.

Legislative History

  • Introduced: November 26, 2024
  • Passed: The bill passed through various legislative stages, including amendments and committee reviews, before being enacted as Act 041 on May 14, 2025.
  • Related Legislation: This bill is related to Senate Bill 1374, which addresses similar issues.

Conclusion

House Bill 1055 represents a significant step towards improving healthcare coverage for individuals affected by Alzheimer’s disease and other dementia-related conditions in Arkansas. By mandating coverage for diagnosis and treatment, the bill aims to facilitate earlier intervention and better management of these diseases, ultimately benefiting both patients and the healthcare system.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.